Last update Sept. 2, 2017
It promotes pancreatic insulin secretion by inhibiting the DPP-4 enzyme that degrades the GLP-1 and GIP intestinal hormones involved in the physiological regulation of glucose, which are activated by eating (EMA 2016, Baetta 2011, Scheen 2011). Administered orally, once a day.
Common side effects are upper respiratory tract infections, urinary tract infections, gastrointestinal disorders, and headaches (EMA, 2016).
Very low risk of hypoglycemia in monotherapy. Very low frequency of clinically significant side effects. Doses up to 80 times higher than normal for 2 weeks did not produce side effects (EMA, 2016).
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic data (EMA 2016, Scheen 2011) and those of its active metabolite (low molecular weight, insignificant protein binding and half-life) make it likely it will pass into breast milk in concentrations that could be significant.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
Diet, exercise, and breastfeeding improve blood sugar levels.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM